. Author manuscript; available in PMC: 2020 May 1.

Published in final edited form as: Neurochem Int. 2019 Feb 26;125:151–162. doi: 10.1016/j.neuint.2019.02.015

Table 1.

Amino acid content in eye as a function of increasing vigabatrin administered subcutaneously

Description	Metabolite	Vehicle	35 mg/kg/d	70 mg/kg/d	140 mg/kg/d
Drug	Vigabatrin	-	6 (1)	16 (1)	29 (1)
Drug-Related	Carnosine	9 (1)	nd	nd	15 (2)
Neutral Amino Acids	Glycine	575 (16)	728 (76)^a	576(16)	618 (19)
	Alanine	530 (12)	671 (77)^a	576 (16)	541 (17)
	Serine	220 (7)	281 (30)^a	250 (16)	249 (12)
	Cysteine	1.3 (1)	nd	nd	23 (1)^a
Basic Amino Acids	Lysine	306 (12)	398 (55)^a	300 (9)	299 (6)
	Citrulline	9 (1)	nd	nd	13 (2)^a
Amines	Phosphoethanolamine	547 (18)	735 (92)^a	576 (16)	591 (12)
	Ethanolamine	46 (2)	61 (7)^a	43 (2)	44 (3)^b

Legend: nmol/g tissue (mean ± (SEM))

p<0.05 compared to vehicle

p<0.05 between 35 and 140 dosing.

Abbreviations: nd, not detected. As an irreversible inhibitor of GABA-transaminase (GABA-T), vigabatrin is predicted to elevate both GABA and β-alanine (the latter a substrate for GABA-T). C arnosine is the L-histidine dipeptide of β-alanine. Animal numbers (n) were: n=21 for vehicle; n=8 for 35 mg/kg/d; n=6 for 70 mg/kg/d; and n=8 for 140 mg/kg/d.